Details of the Drug Combinations

General Information of This Drug (ID: DM9SKW8)

Drug Name

Capivasertib DM9SKW8

Synonyms

AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Triple negative breast cancer	2C60-2C65	Phase 3	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AZD5363 + Ruxolitinib	DCXKTS5	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
AZD5363 + Panobinostat	DC7H9K6	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
------------------------------------------------------------------------------------

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABIRATERONE + AZD5363	DCSEXOP	ABIRATERONE	Prostate Cancer	[5]
Fulvestrant + AZD5363	DC5BWJ0	Fulvestrant	Estrogen Receptor Positive Breast Cancer	[6]
Olaparib + AZD5363	DCLUP4J	Olaparib	BRCA1 Mutation Carrier	[7]
AZD5363 + Enzalutamide	DC50P11	Enzalutamide	Adenocarcinoma of the Prostate	[8]
AZD5363 + Paclitaxel	DCTYZ09	Paclitaxel	Metastatic Breast Cancer	[9]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218197
2	ClinicalTrials.gov (NCT03997123) Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290). U.S. National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7709).
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT04087174) A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
6	ClinicalTrials.gov (NCT01992952) Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
7	ClinicalTrials.gov (NCT02208375) mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
8	ClinicalTrials.gov (NCT02525068) A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
9	ClinicalTrials.gov (NCT02423603) PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer